|Bid||1.49 x 3100|
|Ask||1.50 x 4000|
|Day's Range||1.4500 - 1.5300|
|52 Week Range||1.4500 - 16.5450|
|Beta (3Y Monthly)||2.62|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 8, 2017 - Nov 13, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.00|
Selecta Biosciences, Inc. (SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR (SVP Rapamycin), today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock, at a public offering price of $1.50 per share, before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $30.0 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by Selecta.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 22) Veracyte Inc (NASDAQ: VCYT ) Down In The Dumps (Biotech ...
Selecta Biosciences, Inc. (SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR (SVP Rapamycin), today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Canaccord Genuity and Needham & Company are acting as co-lead managers, and Janney Montgomery Scott is acting as co-manager for the offering. Selecta intends to use the net proceeds from the offering, in addition to its existing cash resources, to advance the clinical development of SEL-212, including the completion of a head-to-head superiority trial of SEL-212 compared to the current FDA-approved uricase therapy, completion of the Phase 2 clinical trial and preparations for a Phase 3 clinical trial, for other pre-clinical programs, including gene therapy development work, and for other operational activities and general corporate purposes.
Selecta Biosciences, Inc. (SELB) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Selecta Biosciences has announced plans to cut more than a third of its employees and shelve a cancer drug following various trial problems late last year. The Watertown biotech said it will eliminate 36 percent of its staff positions as part of a company restructuring. Selecta (Nasdaq: SELB) had 64 full-time employees as of January 2018, according to a federal filing.
“We believe 2019 will be a transformative year for Selecta with key milestones anticipated for both our chronic refractory gout and gene therapy programs. Based on interim data from the recently completed Phase 2 study, inclusive of the five outstanding patients who had not previously completed their course of therapy as of October 9th, 2018, 66% of evaluable patients (21/32), maintained serum uric acid (sUA) levels of
Every investor in Selecta Biosciences Inc (NASDAQ:SELB) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders Read More...
Selecta Biosciences, Inc. (SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that Carsten Brunn, Ph.D. commenced his services as the company’s Chief Executive Officer on December 1, 2018. In connection with the commencement of Dr. Brunn’s services, the company issued to Dr. Brunn an option to purchase an aggregate of 1,000,000 shares of the company’s common stock with a per share exercise price of $6.03, the closing trading price of the company’s common stock on the Nasdaq Global Market on November 30, 2018, and 175,000 restricted stock units.
NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Horizon stock is catching the Street's eye on strong sales of its gout treatment and the potential for an eye disease drug. Horizon stock is up nearly 50% this year.
Selecta Biosciences, Inc. (SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that CFO and Head of Corporate Strategy, John Leaman, M.D., will present at the Stifel Healthcare Conference in New York City at 12:45 p.m. ET on Tuesday, November 13, 2018. A live and archived webcast of the presentation can be accessed via the Investors & Media section of the company’s website, http://selectabio.com. Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. Selecta plans to combine its tolerogenic Synthetic Vaccine Particles (SVP™) to a range of biologics for rare and serious diseases that require new treatment options.
Selecta Biosciences, Inc. (SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that it plans to issue its third quarter 2018 financial results before the open of the U.S. financial markets on Thursday, November 08, 2018. The management team also plans to provide an update on the development strategy for SEL-212, the company’s lead product candidate for the treatment of chronic severe gout, including plans to conduct a head-to-head clinical trial of SEL-212 compared to the current FDA-approved uricase therapy, Krystexxa. Investors and the public can access a live and archived webcast of this call via the Investors & Media section of the company’s website, http://selectabio.com.
Shares of the Watertown biotech continued to slide Wednesday, with the stock dropping more than 40 percent since the company presented new data on their gout drug earlier this week.
According to the company, one patient died after developing pneumonitis, while a second developed a potentially life-threatening buildup of fluid around the heart.
Selecta Biosciences Inc’s (NASDAQ:SELB): Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company’s loss has recently Read More...